IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 250 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $113,827 | -11.9% | 25,017 | +36.4% | 0.00% | – |
| Q2 2023 | $129,134 | -99.2% | 18,343 | -99.3% | 0.00% | -100.0% |
| Q1 2023 | $16,496,896 | -21.7% | 2,699,983 | -18.2% | 0.01% | -27.3% |
| Q4 2022 | $21,082,029 | -57.5% | 3,299,222 | -36.3% | 0.01% | -59.3% |
| Q3 2022 | $49,646,000 | -13.0% | 5,182,146 | +0.3% | 0.03% | -3.6% |
| Q2 2022 | $57,049,000 | -36.4% | 5,167,507 | -4.1% | 0.03% | -22.2% |
| Q1 2022 | $89,686,000 | -19.0% | 5,386,578 | -7.1% | 0.04% | -10.0% |
| Q4 2021 | $110,678,000 | -28.4% | 5,797,716 | -7.5% | 0.04% | -31.0% |
| Q3 2021 | $154,604,000 | -17.8% | 6,269,423 | -13.3% | 0.06% | -19.4% |
| Q2 2021 | $188,049,000 | -34.1% | 7,227,073 | -19.8% | 0.07% | -37.9% |
| Q1 2021 | $285,288,000 | -31.1% | 9,010,970 | +0.9% | 0.12% | -33.7% |
| Q4 2020 | $414,301,000 | +51.3% | 8,928,904 | +7.3% | 0.18% | +31.6% |
| Q3 2020 | $273,846,000 | +35.1% | 8,318,545 | +19.5% | 0.13% | +27.9% |
| Q2 2020 | $202,688,000 | +29.4% | 6,960,434 | +33.1% | 0.10% | -1.0% |
| Q1 2020 | $156,587,000 | +3.3% | 5,230,877 | -4.5% | 0.10% | +31.2% |
| Q4 2019 | $151,624,000 | +26.9% | 5,477,756 | -16.6% | 0.08% | +23.1% |
| Q3 2019 | $119,528,000 | -30.9% | 6,567,476 | -6.9% | 0.06% | -29.3% |
| Q2 2019 | $172,988,000 | +119.6% | 7,054,982 | -14.8% | 0.09% | +119.0% |
| Q1 2019 | $78,789,000 | +7.5% | 8,284,899 | +0.0% | 0.04% | -4.5% |
| Q4 2018 | $73,309,000 | +25.7% | 8,283,464 | +59.8% | 0.04% | +51.7% |
| Q3 2018 | $58,322,000 | -14.2% | 5,184,153 | -2.4% | 0.03% | -17.1% |
| Q2 2018 | $67,955,000 | -24.3% | 5,308,935 | -0.0% | 0.04% | -22.2% |
| Q1 2018 | $89,742,000 | +125.3% | 5,310,163 | +6.6% | 0.04% | +136.8% |
| Q4 2017 | $39,836,000 | -1.3% | 4,979,466 | -4.3% | 0.02% | -5.0% |
| Q3 2017 | $40,341,000 | +6.6% | 5,205,291 | +1.1% | 0.02% | +5.3% |
| Q2 2017 | $37,844,000 | – | 5,148,830 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |